The impact of enzyme replacement therapy on the progression of Pompe disease

G.P.8 An international, phase 3, switchover study of reveglucosidase alfa (BMN 701) in subjects with late-onset Pompe disease B. Schoser *, B. Byrne , F. Eyskens , T. Hiwot , D. Hughes , J. Kissel , E. Mengel , T. Mozaffar , A. Pestronk , M. Roberts , K. Sivakumar , J. Statland , P. Young , C. Heusner , W. Dummer 14 1 Ludwig Maximilians University, Munich, Germany; 2 University of Florida School of Medicine, Gainesville, FL, USA; 3 University Hospital of Antwerp, Antwerp, Belgium; 4 University Hospital Birmingham, Birmingham, UK; 5 Royal Free & University College Medical School, London, UK; 6 Ohio State University, Columbus, OH, USA; 7 Johannes Gutenberg University Mainz, Mainz, Germany; 8 University of California, Irvine, CA, USA; 9 Washington University School of Medicine, Saint Louis, MO, USA; 10 Salford Royal NHS Foundation Trust, Salford, UK; 11 Neuromuscular Research Center, Scottsdale, AZ, USA; 12 University of Kansas Medical Center, Kansas City, KS, USA; 13 University Hospital Munster, Munster, Germany; 14 BioMarin Pharmaceutical Inc., Novato, CA, USA